Detalles de la búsqueda
1.
Integrative analysis of ultra-deep RNA-seq reveals alternative promoter usage as a mechanism of activating oncogenic programmes during prostate cancer progression.
Nat Cell Biol;
2024 Jun 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-38871824
2.
Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial.
Clin Cancer Res;
2024 May 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-38787530
3.
Expert Perspectives on Controversies in Castration-Sensitive Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 1.
JU Open Plus;
2(4)2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38774466
4.
Expert Perspectives on Controversies in Metastatic Castration-Resistant Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 2.
JU Open Plus;
2(4)2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38774467
5.
Prognostic Significance of Immune Cell Infiltration in Muscle-invasive Bladder Cancer Treated with Definitive Chemoradiation: A Secondary Analysis of RTOG 0524 and RTOG 0712.
Eur Urol Oncol;
2024 Apr 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-38641541
6.
CDK12 Loss Promotes Prostate Cancer Development While Exposing Vulnerabilities to Paralog-Based Synthetic Lethality.
bioRxiv;
2024 Mar 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-38562774
7.
ZNF397 Deficiency Triggers TET2-driven Lineage Plasticity and AR-Targeted Therapy Resistance in Prostate Cancer.
Cancer Discov;
2024 Apr 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-38591846
8.
Canonical AREs are tumor suppressive regulatory elements in the prostate.
bioRxiv;
2024 Feb 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-38464162
9.
Single cell-transcriptomic analysis informs the lncRNA landscape in metastatic castration resistant prostate cancer.
NPJ Genom Med;
9(1): 14, 2024 Feb 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-38396008
10.
External Validation of a Digital Pathology-based Multimodal Artificial Intelligence Architecture in the NRG/RTOG 9902 Phase 3 Trial.
Eur Urol Oncol;
2024 Jan 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-38302323
11.
Technical note: Errors introduced when using Dose Voxel Kernels for estimating absorbed dose from radiopharmaceutical therapies involving alpha emitters.
Med Phys;
2024 Feb 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-38314904
12.
Cardiovascular Mortality and Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-term Update of NRG/RTOG 9202.
Eur Urol Focus;
2024 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38307806
13.
Noninvasive Detection of Neuroendocrine Prostate Cancer through Targeted Cell-free DNA Methylation.
Cancer Discov;
14(3): 424-445, 2024 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38197680
14.
Large tandem duplications in cancer result from transcription and DNA replication collisions.
medRxiv;
2024 Jan 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-38260434
15.
Long-term Outcomes of Chemoradiation for Muscle-invasive Bladder Cancer in Noncystectomy Candidates. Final Results of NRG Oncology RTOG 0524-A Phase 1/2 Trial of Paclitaxel + Trastuzumab with Daily Radiation or Paclitaxel Alone with Daily Irradiation.
Eur Urol Oncol;
7(1): 83-90, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-37442672
16.
Multi-institutional Development and External Validation of a Machine Learning Model for the Prediction of Distant Metastasis in Patients Treated by Salvage Radiotherapy for Biochemical Failure After Radical Prostatectomy.
Eur Urol Focus;
10(1): 66-74, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37507248
17.
Transcriptomic Heterogeneity of Expansile Cribriform and Other Gleason Pattern 4 Prostate Cancer Subtypes.
Eur Urol Oncol;
7(2): 222-230, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-37474400
18.
The Impact of Positron Emission Tomography Imaging and Tumor Molecular Profiling on Risk Stratification, Treatment Choice, and Oncological Outcomes of Patients with Primary or Relapsed Prostate Cancer: An International Collaborative Review of the Existing Literature.
Eur Urol Oncol;
7(1): 27-43, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-37423774
19.
Phase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC).
Br J Cancer;
130(1): 53-62, 2024 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37980367
20.
Mortality Risk for Docetaxel-Treated, High-Grade Prostate Cancer With Low PSA Levels: A Meta-Analysis.
JAMA Netw Open;
6(11): e2340787, 2023 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37910103